Cystic Fibrosis: New Insights into Therapeutic Approaches

Author(s): Antonella Tosco, Valeria R. Villella, Valeria Raia, Guido Kroemer, Luigi Maiuri*.

Journal Name: Current Respiratory Medicine Reviews

Volume 15 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Since the identification of Cystic Fibrosis (CF) as a disease in 1938 until 2012, only therapies to treat symptoms rather than etiological therapies have been used to treat the disease. Over the last few years, new technologies have been developed, and gene editing strategies are now moving toward a one-time cure. This review will summarize recent advances in etiological therapies that target the basic defect in the CF Transmembrane Receptor (CFTR), the protein that is mutated in CF. We will discuss how newly identified compounds can directly target mutated CFTR to improve its function. Moreover, we will discuss how proteostasis regulators can modify the environment in which the mutant CFTR protein is synthesized and decayed, thus restoring CFTR function. The future of CF therapies lies in combinatory therapies that may be personalized for each CF patient.

Keywords: CFTR, cystic fibrosis, gene editing, modulators, precision medicine, repositioning therapy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2019
Page: [174 - 186]
Pages: 13
DOI: 10.2174/1573398X15666190702151613

Article Metrics

PDF: 9

Special-new-year-discount